KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Non-cash Items (2016 - 2023)

Historic Non-cash Items for Fulgent Genetics (FLGT) over the last 8 years, with Q4 2023 value amounting to $4.9 million.

  • Fulgent Genetics' Non-cash Items fell 948.34% to $4.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $4.9 million, marking a year-over-year decrease of 948.34%. This contributed to the annual value of $4.9 million for FY2023, which is 948.34% down from last year.
  • Latest data reveals that Fulgent Genetics reported Non-cash Items of $4.9 million as of Q4 2023, which was down 948.34% from $5.4 million recorded in Q4 2022.
  • In the past 5 years, Fulgent Genetics' Non-cash Items ranged from a high of $21.0 million in Q4 2021 and a low of $4.0 million during Q4 2019
  • Its 5-year average for Non-cash Items is $9.9 million, with a median of $5.4 million in 2022.
  • As far as peak fluctuations go, Fulgent Genetics' Non-cash Items skyrocketed by 26575.76% in 2020, and later plummeted by 7414.74% in 2022.
  • Over the past 5 years, Fulgent Genetics' Non-cash Items (Quarter) stood at $4.0 million in 2019, then skyrocketed by 265.76% to $14.5 million in 2020, then soared by 44.75% to $21.0 million in 2021, then crashed by 74.15% to $5.4 million in 2022, then dropped by 9.48% to $4.9 million in 2023.
  • Its Non-cash Items stands at $4.9 million for Q4 2023, versus $5.4 million for Q4 2022 and $21.0 million for Q4 2021.